Key highlights

  • Vectus Biosystems (ASX:VBS) shares were priced at $0.090 as at 1:13 pm GMT+11 on 22 October 2026, down 14.29% on the day and down 40% over a month.
  • On 30 September 2026 the company said the FDA had granted its pre-IND Type B meeting request for VB0004 in idiopathic pulmonary fibrosis.
  • The FDA’s written responses are expected by mid-November 2026.

Vectus Biosystems Ltd (ASX:VBS) shares were priced at $0.090 as at 1:13 pm GMT+11 on 22 October 2026, down 14.29% (down $0.015) on the day, and the share performance data shows the stock down 40% over a month. Vectus is a clinical-stage biotechnology company developing therapies for fibrotic diseases. In an ASX announcement dated 30 September 2026, it said the US FDA had granted a pre-IND Type B meeting for its VB0004 program in idiopathic pulmonary fibrosis (IPF).

About Vectus Biosystems Ltd: Business overview

Vectus Biosystems Limited is a Sydney-based clinical-stage biotechnology company developing novel therapies for fibrotic disease. Its lead candidate, VB0004, is a first-in-class oral vasoactive intestinal peptide (VIP)-mimetic and natriuretic peptide receptor C (NPR-C) agonist being developed for IPF. The company has completed a Phase Ia study in healthy volunteers.

FDA pre-IND meeting granted (30 September 2026)

Vectus announced that the FDA had granted its request for a pre-Investigational New Drug (pre-IND) Type B meeting, in which written responses about its proposed development program for VB0004 in IPF will be tabled. The FDA’s detailed responses are expected by mid-November 2026.

With its US regulatory agent, Cardinal Health Regulatory Services, the company said it would now finalise and submit its meeting package to the FDA.

VB0004 program status

The company said it has completed a Phase Ia clinical study in healthy volunteers establishing a favourable safety and pharmacokinetic profile for VB0004, and that US regulatory activities are now under way to establish the foundation for future clinical development in the US. The announcement said the FDA’s feedback would help inform the next stages of the clinical and regulatory development of VB0004.

Related sector context

Healthcare and medical technology companies are influenced by clinical progress, regulatory pathways, reimbursement decisions and commercial uptake. Earnings reports often include unit sales, Revenue growth, cash use and guidance, and regulatory interactions such as meetings with the US FDA are announced when material. Small companies in the sector can see share price movements driven by news flow and funding conditions.

Risks to weigh in

Clinical-stage biotechnology companies have no product revenue and depend on regulatory feedback, clinical results and funding. An FDA pre-IND meeting provides written guidance but does not confirm that a trial will proceed or succeed. Share prices of very small companies can move sharply on modest volumes, and a decline of 40% over a month, as in the data supplied, shows how large such moves can be.

Catalysts on watch

The FDA’s written responses, expected by mid-November 2026.

Submission of the meeting package and the company’s subsequent development plan for VB0004 in IPF.

Funding announcements and quarterly cash updates.

Final word

Vectus’s share performance data shows a one-month decline of 40% and a further fall on the day, while its latest announcement describes a scheduled FDA meeting process for VB0004. The FDA’s written responses will be the next regulatory data point.